N/A
N=19
Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease
Parkinson Disease
Bottom Line
View on ClinicalTrials.gov: NCT05948956 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Change in Duration of 80 Rpm Endurance Test — 26.31; 25.84; 15.62; 12.12 minutes
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ketone Ester Beverage (Dietary_supplement); Electrolyte Beverage (Dietary_supplement); Cycling Intervention (Behavioral)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- All
- Sponsor
- University of Michigan
- Primary completion
- Mar 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Duration of 80 Rpm Endurance Test |
26.31; 25.84; 15.62; 12.12; 31.89; 33.21 | — |
| PRIMARY Change in Oxygen Uptake (VO2 Max) |
19.44; 19.87; 19.30; 18.75; 18.80; 19.15 | — |
Summary
The main purpose of this study is to assess changes in exercise capacity in people with Parkinson's disease before and after an exercise training program with ketone ester supplementation.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of Parkinson's Disease
Exclusion Criteria
- Any recent changes in EKG, history of myocardial infarction or other cardiac event or other cardiac contraindications to exercise
- Inability to use a step, stand, walk, or use a stationary cycle ergometer
- History of symptoms in exercise that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, painful neuropathy, significant ankle edema or medication side effects
- History of symptomatic cardiovascular or pulmonary disease interfering with exercise
- History of active rheumatoid arthritis
- History of uncontrolled chronic pain syndrome
- Any other history of medical or psychiatric comorbidity precluding safe participation in the project
- Poorly controlled diabetes
- Pregnancy or breastfeeding
- Clinically significant dementia
- Any contraindications to MRI (metal implants, severe claustrophobia, inability to lie still for 1 hour, etc.)
Data sourced from ClinicalTrials.gov (NCT05948956). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.